BIOHAVEN LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.69 USD | -13.71% |
|
-12.29% | -16.61% |
| 10/05 | Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates | MT |
| 25/04 | Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 946.1 | 3,434 | 3,151 | - | - |
| Enterprise Value (EV) 1 | 480.7 | 3,052 | 2,743 | 2,739 | 2,674 |
| P/E ratio | -1.09 x | -7.47 x | -4.98 x | -5.93 x | -7.51 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 315 x | 219 x | 26.1 x |
| EV / Revenue | - | - | 274 x | 190 x | 22.1 x |
| EV / EBITDA | -0.85 x | -7.11 x | -6.13 x | -5.2 x | -6.83 x |
| EV / FCF | -1.58 x | -9.12 x | -8.58 x | -4.38 x | -10.3 x |
| FCF Yield | -63.2% | -11% | -11.7% | -22.8% | -9.7% |
| Price to Book | 1.15 x | 8.11 x | 7.78 x | 8.92 x | 8.2 x |
| Nbr of stocks (in thousands) | 68,161 | 80,234 | 88,292 | - | - |
| Reference price 2 | 13.88 | 42.80 | 35.69 | 35.69 | 35.69 |
| Announcement Date | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10.01 | 14.39 | 120.8 |
| EBITDA 1 | - | -566.5 | -429.1 | -447.2 | -526.8 | -391.2 |
| EBIT 1 | - | -567.9 | -436.1 | -671.5 | -596.2 | -515.3 |
| Operating Margin | - | - | - | -6,709.8% | -4,144% | -426.6% |
| Earnings before Tax (EBT) 1 | - | -569.8 | -409.6 | -634.6 | -593.1 | -510.4 |
| Net income 1 | -236.4 | -570.3 | -408.2 | -622.2 | -582.7 | -499.5 |
| Net margin | - | - | - | -6,216.79% | -4,050.23% | -413.54% |
| EPS 2 | -6.940 | -12.75 | -5.730 | -7.170 | -6.017 | -4.751 |
| Free Cash Flow 1 | - | -303.8 | -334.8 | -319.8 | -625.6 | -259.3 |
| FCF margin | - | - | - | -3,195.43% | -4,348.44% | -214.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 10/08/22 | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | 0.00167 | 11.12 | 4.216 | 4.254 |
| EBITDA 1 | - | - | - | - | - | -151.8 | -181.8 | -110.7 | -111.9 | -117 | -128.1 | -131.2 |
| EBIT 1 | -67.64 | -213.4 | -77.78 | -94.01 | -110.5 | -153.7 | -183.2 | -170.8 | -163.3 | -154.2 | -146.8 | -147 |
| Operating Margin | - | - | - | - | - | - | - | - | -97,78,792.22% | -1,386.65% | -3,482.21% | -3,454.9% |
| Earnings before Tax (EBT) 1 | -67.64 | -215.2 | -69.55 | -88.17 | -105.9 | -146 | -178.9 | -167.3 | -159.6 | -151.1 | -149.2 | -149.1 |
| Net income 1 | -67.64 | -201.1 | -70.49 | -90.35 | -102.6 | -144.8 | -179.5 | -167.3 | -159.6 | -151.1 | -144.1 | -144.8 |
| Net margin | - | - | - | - | - | - | - | - | -95,59,840.12% | -1,359.32% | -3,419.06% | -3,404.38% |
| EPS 2 | -1.750 | -3.320 | -1.030 | -1.320 | -1.500 | -1.810 | -2.200 | -1.886 | -1.736 | -1.619 | -1.634 | -1.746 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/22 | 23/03/23 | 12/05/23 | 31/07/23 | 14/11/23 | 29/02/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 465 | 382 | 408 | 412 | 477 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -304 | -335 | -320 | -626 | -259 |
| ROE (net income / shareholders' equity) | - | -199% | -78.5% | -109% | -142% | -105% |
| ROA (Net income/ Total Assets) | - | -142% | -64.6% | -72% | -70.2% | -71.3% |
| Assets 1 | - | 401.9 | 632.1 | 863.6 | 829.8 | 700.5 |
| Book Value Per Share 2 | - | 12.00 | 5.280 | 4.590 | 4.000 | 4.350 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 6.07 | 3.05 | 4 | 8.26 | 6.41 |
| Capex / Sales | - | - | - | 39.97% | 57.44% | 5.31% |
| Announcement Date | 10/08/22 | 23/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
35.69
USD
Average target price
57.67
USD
Spread / Average Target
+61.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.61% | 3.15B | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- BHVN Stock
- Financials Biohaven Ltd.
